RxDoctor Payments Data

Gregory Petro, MD

Cardiovascular Disease · McDonough, GANPI 1124023304

Payments from drug & device makers

$4,326in general payments, 2019–2025

Across 256 payments — averaging $16.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$772
  • E.r. Squibb & Sons, L.L.C.$635
  • Novartis$463
  • AstraZeneca$357
  • Abiomed$288
  • Amgen$228
  • plus $2K from 21 others

What the payments were for

  • Food & beverage$4,20697%
  • Education$1203%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,326 in reported general payments places this provider in the 60th percentile of 640 cardiovascular disease providers in Georgia.

See all cardiovascular disease providers in Georgia

Medicare billing

Part B allowed, 2024
$443,849
Medicare patients
1,049
Services billed
4,232

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban439$509,932
EntrestoSacubitril/Valsartan125$170,955
XareltoRivaroxaban116$120,966
Repatha SureclickEvolocumab55$51,804
OzempicSemaglutide35$39,645
MounjaroTirzepatide29$34,350
JardianceEmpagliflozin20$22,509
BrilintaTicagrelor36$21,705
Metoprolol Succinate480$6,131
MyrbetriqMirabegron12$5,196
Atorvastatin Calcium580$4,798
Torsemide321$4,113
Bisoprolol Fumarate180$3,864
Amiodarone Hcl142$3,625
ClopidogrelClopidogrel Bisulfate339$3,274

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$174$509,932439 claims
NovartisEntresto$463$170,955125 claims
Johnson & JohnsonXarelto$772$120,966116 claims
Novo NordiskOzempic$59$39,64535 claims
Lilly USA, LLCMounjaro$18$34,35029 claims
Boehringer IngelheimJardiance, Pradaxa$106$24,56431 claims
AstraZenecaBrilinta$357$21,70536 claims
Astellas Pharma US IncMyrbetriq$100$5,19612 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 640 cardiovascular disease providers in Georgia.

Other cardiovascular disease in McDonough

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →